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Background: MDM2 gene polymorphisms 285G/C and 344 T/A are two single nucleotide polymorphisms (SNPs)
recently identified as important variants that could influence the expression of MDM2 gene through the
modulation of transcription factors binding on the SNP309T/G. The 285C variant seems to present a geographically
distinct distribution in humans and to be associated with a low cancer risk. In the present report, we studied the
distribution of the three SNPs in a population with low liver cancer incidence.
Methods: A group of 119 patients with hepatocellular carcinoma (HCC, 63.45 ± 12.59 year, 26–80) and another
of 103 non-HCC controls (56 ± 10.82 year, 22–79) were enrolled to investigate association between MDM2
polymorphisms and susceptibility to develop HCC. The three studied SNPs (285G/C, 309 T/G and 344 T/A) were
genotyped using polymerase chain reaction and sequencing techniques.
Results: Genotypes and alleles distributions of the three studied polymorphisms of MDM2 were not significantly
different between cases and controls. An increased risk of HCC development was found in case of 309G allele
presence albeit without reaching the significance (29.8% vs 22.3%, OR = 1.48, 95% CI, 0.96-2.27, p = 0.073). In
addition, neither 285C nor 344A MDM2 variants were significantly associated with an increased risk of HCC
(p = 0.688 and p = 1 respectively). Remarkably, we found that the supposedly Caucasian-specific 285C variant was
present in 1% of the Moroccan population.
Conclusions: This is the first study of the MDM2 SNP285G/C and SNP344T/A polymorphisms in association with
HCC development. In contrast with previous studies, showing that females carrying SNP285C variant have a
significantly reduced risk of developing breast, ovarian and endometrial cancer, no significant modulation of HCC
risk was found in a North-African population.
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Hepatocellular carcinoma (HCC), is the most frequent
primary liver tumor, with a high incidence in Africa and
Asia, which makes it the fifth human malignancy and
the third most common cause of cancer-related mor-
tality [1,2]. It is well established that HCC results from
a complex tumorigenic process that occurs on a back-
ground of genetic and epigenetic alterations where envir-
onment (hepatitis viruses, aflatoxins) and lifestyle (alcohol* Correspondence: soumaya.benjelloun@pasteur.ma
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Morocco is a country of intermediate endemicity for chro-
nic infections with hepatitis B (HBV) and C (HCV) viruses
[6-8], where a consistently low level of food contamin-
ation by aflatoxins B1 [9,10]. In addition, the level of al-
cohol consumption is known to be historically low in
Moroccans [11]. Despite this medium prevalence of chro-
nic hepatitis, still the most important risk factor of HCC
worldwide, the incidence of liver cancer in Morocco is
known to be one of the lowest in the world (1.2 case/105
habitants, ASR) [12].
The low impact of environmental and lifestyle risk fac-
tors on HCC incidence in Morocco attenuates their rolel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,






Age (Mean ± SD) 63.45 ± 12.59 56 ± 10.82
Sex ratio (M:F) 1.53 (72/47) 1.29 (58/45)
Ongoing co-infection HBV + HCV 4 (3.4) 0
Chronic hepatitis B (HBsAg+) 12 (10.1) 0
Chronic hepatitis C (anti-HCV+) 76 (63.9) 0
Resolved Hepatitis B
(HBsAg-/anti-HBc+)
40 (33.6) 30 (29.1)
No history of hepatitis B or C 15 (12.6) 73 (70.9)
Type 2 Diabetes 7 (5.9) 1 (0.9)
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situation to detect individual susceptibility. Actually, in-
dividual susceptibility to HCC has been already studied
in various populations and germinal variants of several
genes were earmarked as associated with susceptibility
[13-15]. Beside the TP53 gene and its Arg72Pro po-
lymorphism, MDM2 gene, a negative regulator of the
former with the SNP 309 T > G in the promoter region,
is associated with hepatocellular carcinoma [16]. This
SNP was described for the first time by Bond et al.
(2004), to be associated with accelerated tumor forma-
tion, and then studied in a multitude of cancers [17,18].
In HCC, the 309 T > G SNP was profiled in different
ethnic groups. To sort out some inconsistencies, an inte-
resting meta-analysis was conducted in 2012 [19]. Seven
different studies, including one survey on the Moroccan
population, were evaluated [16]. This meta-analysis con-
firms the predisposing effect of MDM2 309G variant to
HCC [19]. Another polymorphism on MDM2, 344 T > A
SNP was identified in 2004 as accelerating tumor forma-
tion [17]. Recently, a G > C SNP located 24 base pair up-
stream the 309G > T SNP was described concomitantly
by Knappskog et al. and Paulin et al. This 285C variant
was found to antagonize the binding effect of SNP309T
on Sp1 transcription factor [20,21].
Thus, the present report aims to describe the profiling
of the three MDM2 SNPs together for the first time
in HCC patients and non-HCC controls recruited in
Morocco.
Methods
After giving written informed consent for genetic test-
ing, every participant was interviewed. The study proto-
col was evaluated and approved by the ethics Committee
of the Faculty of Medicine of Casablanca and the study
was conducted in accordance with the ethical guidelines
of the 1975 Declaration of Helsinki as reflected in a
priori approval by the institution's human research com-
mittee. A total of 119 HCC patients and 103 controls
were analyzed for the MDM2 SNPs 285 (rs117039649),
309 (rs2279744) and 344 (rs1196333). The controls did
not have a previous history of cancer of any type. Blood
was collected in EDTA tubes; sera were prepared for
ELISA tests and leucocytes for DNA extraction. Sero-
logical markers for hepatitis viruses were tested with
commercially available kits (Axsym, Abbott Diagnostics,
Germany) for HBsAg, anti-HBc and anti-HCV for HCC
patients and non-HCC controls.
Genomic DNA was isolated from whole blood leuco-
cytes. After washing in Tris/EDTA (TE) buffer, samples
were submitted to digestion in SDS/proteinase K buffer
at 37°C for 16 h maximum, followed by phenol/chloro-
form extraction. DNA was then ethanol-precipitated and
re-suspended in TE buffer, as described previously [16].MDM2 polymorphisms were genotyped using an amp-
lification followed by sequence analysis (PCR-Sequen-
cing). Briefly, a step-down amplification was performed
at annealing temperature of 55°C. The polymerase chain
reaction was performed with a set of primers forward 5’-
CCCGGACGATATTGAACA-3’ and reverse 5’-AGAA
GCCCAGACGGAAAC-3’. The fragment was amplified
in a 25 ml reaction volume using 0.2 mM primers,
200 mM dNTP and 1 U Taq polymerase. PCR products
were loaded on a 2% agarose gel stained with ethidium
bromide and a 226-bp strip was revealed. Positive PCR
products were purified using the Exonuclease I/Shrimp
Alkaline Phosphatase (GE Healthcare) and sequenced
using BigDye Terminator version 3.1 kits and an ABI
PRISM 3130 DNA automated sequencer (Applied Bio-
systems, Foster City, CA, USA). Nucleotide sequences
were analyzed using SeqScape®v2.5 software (Applied
Biosystems, Foster City, CA, USA).
Using a Chi-square test, Departures from Hardy–
Weinberg equilibrium were determined in all groups for
each SNP genotype distribution. Mann–Whitney test was
conducted to compare medians. The significance of asso-
ciations between genotype/alleles variants and susceptibil-
ity to HCC were assessed using Chi-square and Fisher’s
tests with an estimation of the risk by computing ORs and
their 95% CIs. A p-value <0.05 was considered statistically
significant. All tests were two-sided. Haplotype frequen-
cies and pairwise differences between groups’ analyses
were performed using Arlequin 3.0 software, on the base
of permutation tests using the EM algorithm [22].
Results
Demographic features of subjects
In the present report, we studied three SNPs on MDM2
gene, in 119 HCC patients (63.45 ± 12.59 year, 26–80)
and 103 controls (56 ± 10.82 year, 22–79). Table 1 sum-
marizes general characteristics of the studied groups.
Over 63% of the patients were positive for anti-HCV
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tients. Another subset of patients (33.6%) was negative
for HBsAg but presented a history of HBV infection,
and 3.4% of cases were coinfected with HBV/HCV.
About 6% of cases had type 2 diabetes mellitus. The
mean tumor diameter was 3.5 ± 2.6 cm. The group of
controls includes 103 volunteers without any history
of cancer.Genotypes and alleles distribution
Allelic distributions in both patients and controls were
in Hardy-Weinberg equilibrium (p > 0.05). Genotypes
and alleles frequencies are presented in Figure 1. The
first SNP (rs117039649) is a G/C substitution in position
285 of the MDM2 promoter region. The dominant ge-
notypic form was GG with 96.6% of cases and 98% of
controls, the remaining 3.4% of cases and 2% of controls
were GC heterozygotes (OR = 1.757, 95% CI, 0.315-
9.793, p = 0.688). Thus, out of the 222 profiled individ-
uals, none present the genotype CC at rs117039649. For
the rs2279744 (309 T/G), an increased risk of HCC was
found in case of G allele presence. This risk did not
reach, however, the level of significance (29.8% vs 22.3%,
OR = 1.48, 95% CI, 0.96-2.27, p = 0.073). The same was
true for patients carrying G/G genotype (OR = 2.63,
95% CI, 0.78-8.85, ns). The third SNP was rs1196333,
an A/T substitution on the position 344. The major
genotype was TT, whereas the TA genotype was present
in 7.6% of cases and 7.8% of controls (OR = 1.118, 95% CI,
0.020-62.734, p = 1).Figure 1 Genotype and allelic distribution of 285G/C, 309 T/G
and 344A/T in Moroccans with and without HCC.Linkage disequilibrium and haplotype analysis
We calculated frequencies of genotypes combinations
in both patients and controls for the three SNPs of
MDM2 in the order of SNPs on the chromosome 12q15
(rs117039649, rs2279744 and rs1196333). Only 7 and 6
out of 27 possible combinations were present in patients
and in controls groups, respectively. In HCC patients,
we observed 4 (3.4%) patients with 285GC genotype,
all of them carrying at least a G at SNP309 and 344TT.
On the opposite, the nine (7.6%) 344TA patients were
285GG and carrying at least a T at SNP309. Proportions
were approximately the same in controls group and no
significant haplotype association with HCC was found
(p > 0.05, Table 2). The three SNPs are located within pro-
moter P2 of MDM2 gene, delimiting a region of 59 bp.
A linkage analysis for these SNPs in 222 Moroccan in-
dividuals (HCC patients and controls) was performed
(see Figure 2). Given the LD analysis, 285C is linked
to 309G (p = 0.002), whereas the 344A is linked to
309 T (p = 0.025).
Only four out of the eight possible haplotypes were
observed in patients and controls. Rare haplotypes were
present in the Moroccan population: a CGT haplotype
(1%) and a GTA haplotype (3.9%). Table 3 shows haplo-
types distribution in both patients and controls groups.
Importantly, no haplotypic distribution difference was
noticed between patients and control individuals.
Discussion
Research on HCC came through various eras of genetic
and molecular advances but our understanding of the
mechanistic process driving liver carcinogenesis remains
incomplete due to the tremendous heterogeneity of this
disease. Many studies focused on the p53 pathway con-
sidered as the major target undergoing aberrations in
liver carcinogenesis. One of the most important regu-
lators of the pathway is MDM2 (Mouse double mi-
nute 2 homolog), an E3 ubiquitin ligase that targets
the p53 protein for proteasomal degradation. Several
studies have shown previously that polymorphic variantsTable 2 Distribution of Genotype combinations of the
SNPs 285G/C, 309 T/G and 344 T/A among HCC patients
and controls
Genotype combinations HCC(%) n = 119 Controls (%) n = 103
GC/GG/TT 1 (0.9) 0 (0.0)
GC/TG/TT 3 (2.5) 2 (1.9)
GG/TG/TA 2 (1.7) 2 (1.9)
GG/GG/TT 9 (7.6) 4 (3.9)
GG/TG/TT 46 (38.6) 34 (33)
GG/TT/TA 7 (5.9) 6 (5.8)
GG/TT/TT 51 (42.8) 55 (53.45)
Figure 2 Pairwise linkage analysis of studied polymorphisms
based on permutation tests using EM algorithm.
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status [23]. Recently, new SNPs on MDM2 were discov-
ered and shown to be associated with different cancer
types [24,25].
In the present report, we investigate, for the first time,
the potential role of SNPs 285G/C (rs117039649) and
344 T/A (rs1196333) on hepatocellular carcinoma.
In the initial study of Knappskog et al., SNP 285C
(rs117039649) was described as an exclusively Caucasian
variant when comparing a cohort of Chinese individuals
to a Caucasian multi-cohort (Norway, Netherlands, UK
and Finland). No data from African or American natives
was available though. This variant is in complete linkage
with the 309G variant [24]. Here, we report the presence
of the 285C variant in the Moroccan population embed-
ded within a single CGT haplotype. The haplotype fre-
quencies, 1% in controls and 1.7% in the HCC group are
not significantly different. Whereas the 285C variant is
present in almost 12% of North Europeans carrying the
309G variant [25], we found a rate of 4.7% among controlsTable 3 Haplotype frequencies for MDM2 gene SNPs




HCC n = 119 Controls n = 103 p-values
GTT 66.8 73.7 0.244
GGT 27.7 21.4 0.281
GTA 3.8 3.9 1
CGT 1.7 1 1and 6.5% among HCC patients recruited in a Moroccan
population. It is known that the 309G variant is en-
hancing the binding of Sp1 transcription factor to its
promoter, increasing therefore MDM2 expression and
accelerating tumor formation. Functional studies reported
that SNP285C reduces significantly promoter binding by
Sp1 attenuating the effect of 309G variant. This observa-
tion was consistently made on different sets of tumors
(ovarian, endometrial and breast cancers but not lung tu-
mors) in the same ethnic group [24,26]. For the SNP344
(rs1196333), no association was shown between variants
and ovarian, endometrial, breast or prostate cancers, des-
pite in silico data showing that 344A variant seems to
modulate the binding of TFAP2A, SPIB and AP1 tran-
scription factors [20]. The SNP344T is always associated
with the SNP309T allele; its status may not affect hepato-
cellular carcinoma risk (p > 0.05).
One interesting feature to discuss in this paper is the
allelic distribution of 285G/C and 344A/T. The 285C
variant was initially thought to be restricted to North
European Caucasian populations and considered as such
as a relatively recent polymorphism. This allele is, how-
ever, also present in the Moroccan population (1%), a
situation that could be explained by a genetic admixture
from Western Europe (Spanish, Portuguese or French
populations) or by the original presence of SNP285 at
this rate in North Africa as it is observed for the habi-
tants of Helsinki in North-Eastern Europe (1.6%). The
analysis of SNP285 prevalence in Middle-Eastern popula-
tion may bring an answer this question. On the contrary,
The SNP 344A variant is more frequent in Africans (18%
in a group of African Americans) than Caucasians and
Asians (3%), and might be an ancient polymorphism evol-
ving similarly to 309 T/G polymorphism [20]. In the pre-
sent study, we found, as expected, a frequency of 344A
allele similar to that measured in Caucasians (4.4%).
These findings are in keeping with the previous obser-
vations of Pineau et al., and Ezzikouri et al. about the
molecular context of HCC in Moroccan patients [16,27].
These authors suggested that given the similarity bet-
ween populations, the genetic component alone could
not provide an explanation the differences of HCC inci-
dence observed between Morocco (0.8 case/105 habi-
tants) or Western North Africa (1 case/105 habitants),
and the Northern Bank of the Mediterranean (≥10 cases/
105 habitants) [28]. Intriguingly, the prevalence of chro-
nic hepatitis, the principal risk factor for HCC world-
wide, is higher in Western North Africa than in most if
not all European countries, a situation suggesting that
underestimated risk factors present in Europe may pro-
vide the decisive thrust towards tumor development [29].
Thus, further areas must be explored, i.e. epigenetics,
transcriptional and proteomic profiling in line with viral
characteristic. Any kinds of data must be gathered in a
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ing liver carcinogenesis in the rather specific context of
North African populations known to be submitted to a
South–north gradient of sub-Saharan genes but sharing as
well an extensive genetic background with them Northern
Mediterranean neighbors [30,31].
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